SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am. J. Psychiatry 1994; 151: 133135.
  • 2
    Zarate CA, Tohen M. Antipsychotic drug treatment in first-episode mania: A 6-month longitudinal study. J. Clin. Psychiatry 2000; 61: 3338.
  • 3
    Chou JC, Czobor P, Charles O et al. Acute mania: Haloperidol dose and augmentation with lithium or lorazepam. J. Clin. Psychopharmacol. 1999; 19: 500505.
  • 4
    Kane JM, Jeste DV, Barnes TRE et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. American Psychiatric Press, Washington, DC, 1992.
  • 5
    Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch. Gen. Psychiatry 1986; 43: 342346.
  • 6
    Nasrallah HA, Churchill CM, Handan-Allan CA. Higher frequency of neuroleptic-induced dystonia in mania than schizophrenia. Am. J. Psychiatry 1988; 145: 14551456.
  • 7
    Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am. J. Psychiatry 2004; 161: 414425.
  • 8
    Keck PE Jr, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 2003; 160: 16511658.
  • 9
    Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HEGH study group. Am. J. Psychiatry 1999; 156: 702709.
  • 10
    Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: A double-blind, placebo-controlled study. Br. J. Psychiatry 2005; 187: 229234.
  • 11
    Keck PE Jr, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Ziprasidone in mania study group. Am. J. Psychiatry 2003; 160: 741748.
  • 12
    Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr. Atypical antipsychotics in the treatment of mania: A meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry 2006; 67: 509516.
  • 13
    Harada T, Otsuki S. Antimanic effect of zotepine. Clin. Ther. 1986; 8: 406414.
  • 14
    Amann B, Sterr A, Mergl R et al. Zotepine loading in acute and severely manic patients: A pilot study. Bipolar Disord. 2005; 7: 471476.
  • 15
    Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br. J. Psychiatry 1978; 133: 429435.
  • 16
    Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1976; 6: 278296.
  • 17
    Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol. Bull. 1988; 24: 9799.
  • 18
    Guy W. Clinical Global Impression (CGI). In : GuyW. (ed.). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD, 1976; 218222.
  • 19
    Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970; 45: 1119.
  • 20
    Barnes TRE. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989; 154: 672676.
  • 21
    Guy W. Abnormal Involuntary Rating Scale (AIMS). In : GuyW. (ed.). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD, 1976; 534537.
  • 22
    Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 2002; 159: 11461154.
  • 23
    Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilizer plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomized controlled trial. Br. J. Psychiatry 2003; 182: 141147.
  • 24
    Tohen M, Chengappa KN, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry 2002; 59: 6269.
  • 25
    Sachs G, Chengappa KN, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004; 6: 213223.
  • 26
    Cooper SJ, Tweed J, Raniwalla J, Butler A, Welch C. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr. Scand. 2000; 101: 218225.
  • 27
    Hwang TJ, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: A double-blind comparison with haloperidol. J. Formos. Med. Assoc. 2001; 100: 811816.
  • 28
    Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: A parallel-group double-blind trial. Psychopharmacol. Bull. 1996; 32: 8187.
  • 29
    Yoshida H, Kaiya H, Kondo T, Sanpei F, Takeda N, Takeuchi K. [Effects of zotepine, a psychotropic agent, on the serum uric acid level of inpatients at a psychiatric hospital]. Yakubutsu Seishin Kodo 1982; 2: 6976 (in Japanese).